Wire · opportunities
Tempus AI Stock (TEM) Opinions on Recent AI Model Publications and Collaborations
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 August 2026 · Fusion42 review
Tempus AI gained investor attention following a new collaboration with CellCarta, publication of the PRISM2 AI model, and a strong Q2 2026 with revenue up 21.56%. Despite insider sales, major institutional investors like JPMorgan Chase and Goldman Sachs significantly increased their holdings, highlighting confidence in Tempus AI's positioning in AI-enabled drug discovery and precision medicine.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Tempus AI's collaboration and new AI model data mark a clear chance for you in biotech-focused drug discovery. Institutional backing and quarterly growth are your green lights to position products around AI-driven precision medicine now.
◆ Coverage
1 source · 16 Aug 2026
◆ Related on Wire
◆ Topics